Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2011-07-05
2011-07-05
Qian, Celine (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C536S024320
Reexamination Certificate
active
07972775
ABSTRACT:
Progressive multifocal leukoencephalopathy (PML) has been identified in patients taking natalizumab (NMAB) for the treatment of multiple sclerosis (MS). This patent application provides a novel method of patient screening and monitoring intended to decrease the risk of PML and other opportunistic central nervous system (CNS) diseases in patients undergoing MS therapy with NMAB, and proposes a novel method of screening and monitoring intended to decrease the risk of opportunistic disease processes of the CNS during the treatment of other medical disorders with NMAB.
REFERENCES:
patent: 2005/0095246 (2005-05-01), Shafer
Colucci et al (Journal of the Neurological Sciences, 2004. vol. 217, pp. 107-110).
Sepkowitz (CID, 2002, vol. 34, pp. 1098-1107).
FDA approved package insert for Tysabri as of Mar. 2005, 11 pgs.
Hammarin, et al., “Analysis of PCR as a Tool for Detection of JC Virus DNA in Cerebrospinal Fluid for Diagnosis of Progressive Multifocal Leukoencephalopathy”,Journal of Clinical Microbiology, 34(12):2929-2932, Dec. 1996.
McGuire, et al., “JC Virus DNA in Cerebrospinal Fluid of Human Immunodeficiency Virus-infected Patients: Predictive Value for Progressive Multifocal Leukoencephalopathy”,Annals. of Neurology, 37(3):395-399, Mar. 1995.
De Luca, et al., “Improved Detection of JC Virus DNA in Cerebrospinal Fluid for Diagnosis of AIDS-Related Progressive Multifocal Leukoencephalopathy,”Journal of Clinical Microbiology, 34(5):1343-1346, May 1996.
“JC Virus DNA PCR for Diagnosis of PML”,Clinical Virology Laboratory Newsletter, from the Department of Laboratory Medicine—Yale-New Haven Hospital Medical Center, 14(1), Jan. 2005, 2 pgs.
De Viedma, et al., “Dual Qualitative-Quantitative Nested PCR for Detection of JC Virus in Cerebrospinal Fluid: High Potential for Evaluation and Monitoring of Progressive Multifocal Leukoencephalopathy in AIS Patients Receiving Highly Active Antiretroviral Therapy”,Journal of Clinical Microbiology, 37(3):724-728, Mar. 1999.
Koralnik, et al., “JC Virus DNS load in Patients With and Without Progressive Multifocal Leukoencephalopathy”,Neurology, vol. 52, Issue 2, Jan. 1999, 14 pgs.
Ryschkewitsch, et al. “Comparison of PCR-Southern Hybridization and Quantitative Real-Time PCR for the Detection of JC and BK Viral Nucleotide Sequences in Urine and Cerebrospinal Fluid”,Journal of Virological Methods121(2):217-221, 2004.
Vago, et al., “JCV-DNA and BKV-DNA in the CNS Tissue and CSF of AIDS Patients and Normal Subjects. Study of 41 Cases and Review of the Literature”,Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 12:139-146, 1996.
Safdar, et al., “Fatal Immune Restoration Disease in Human Immunodeficiency Virus Type 1-Infected Patients with Progressive Multifocal Leukoencephalopathy: Impact of Antiretroviral Therapy-Associated Immune Reconstitution”, Clinical Infectious Diseases, 35:1250-7, Nov. 15, 2002.
Ferrante, et al., “Detection of JC Virus DNA in Cerebrospinal Fluid from Multiple Sclerosis Patients”,Multiple Sclerosis, 4:49-54, 1998.
Giudici, et al., “Highly Active Antiretroviral Therapy and Progressive Multifocal Leukoencephalopathy: Effects on Cerebrospinal Fluid Markers of JC Virus Replication and Immune Response”,Clinical Infectious Diseases, 30:95-99, 2000.
Bowers, “Progressive Multifocal Leukoencephalopathy”,Bulletin of Experimental Treatments for AIDS, by the San Francisco AIDS Foundation, Sep. 1997, 12 pgs.
Frohman, et al., “The Utility of MRI in Suspected MS—Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology”, Neurology, 61:602-611, 2003.
Kappos, et al., “Natalizumab Treatment for Multiple Sclerosis: Recommendations for Patient Selection and Monitoring”,Lancet Neurology, 6:431-441, May 2007.
Yousry, et al., “Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy”,The New England Journal of Medicine, 354(9):924-933, 2006.
Rudick, et al., “Natalizumab Plus Interferon Beta-1a for Relapsing Multiple Sclerosis”,The New England Journal of Medicine, 354(9):911-923, 2006.
Polman, et al., “A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis”,The New England Journal of Medicine, 354(9):899-910.
Biogen/Elan website. Touch program to monitor patients using Tysabri (as required by the FDA when Tysabri returned to market): http://tysabri.com/tysbProject/tysb.portal/—baseurl/twoColLayout/SCSRepository/en—US/tysb/home/touch/index.html.
“Public Health Advisory—Suspended Marketing of Tysabri (Natalizumab),” Feb. 28, 2005, retrieved from the Internet Oct. 2, 2009: URL:http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051761.htm, 3 pp.
Hans et al., “Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy,”New England Journal of Medicine, vol. 361, No. 11, Sep. 10, 2009, pp. 1081-1087.
Iacobaeus et al., “Analysis of Cerebrospinal Fluid and Cerebrospinal Fluid Cells From Patients With Multiple Sclerosis for Detection of JC Virus DNA,”Multiple Sclerosisvol. 15, No. 1, Jan. 1, 2009, pp. 28-35.
Langer-Gould et al., “Progressive Multifocal Leukoencephalopathy in a Patient Treated With Natalizumab,”New England Journal of Medicine, vol. 353, No. 4, Jul. 28, 2005, pp. 375-381.
Lima et al., “New Features of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy and Natalizumab,”Journal of Neurovirology, vol. 11, No. Suppl. 3, 2005, pp. 52-77.
Noseworthy et al., “Natalizumab,”Nature Reviews, vol. 4, No. 2, Feb. 1, 2005, retrieved from the Internet Oct. 2, 2009: URL:http://www.nature.com
rd/journal/v4
2/full
rd1637.html, 6 pp.
Van Assche et al., “Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease,”The New England Journal of Medicine, Jul. 28, 2005, vol. 353, No. 4, pp. 362-368.
Supplementary European Search Report for EP Application No. EP 06 76 970, completed Dec. 3, 2009, 3 pgs.
Dalton et al., “Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis,”Journal of Neurovirology, 2004, vol. 251, pp. 407-413.
Doggrell, S.A., “Is natalizumab a breakthrough in the treatment of multiple sclerosis?”Expert Opinions in Pharmacotherapy, 2003, vol. 4, No. 6, pp. 999-1001.
Du Pasquier et al., “A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and early control of progressive multifocal leukoencephalopathy,”Brain, 2004, vol. 127, pp. 1970-1978.
Sheridan, C., “Fast track to MS drug,”Nature Biotechnology, Aug. 2004, vol. 22, No. 8, pp. 939-941.
Steiner, PML: underdiagnosed in MS patients on natalizumab, The Lancet Neurology, vol. 9, Issue 6, p. 564, Jun. 2010.
Sadiq, JCV detection in multiple sclerosis patients treated with natalizumab, J Neurology, Jan. 7, 2010.
Iacobeous, Analysis of cerebrospinal fluid and cerebrospinal cells from patients with multiple sclerosis for detection of JC virus DNA, Multiple Sclerosis 2009; 15:28-35.
Linda, Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy, N Engl J Med 2009; 361:1081-7.
Communication dated Apr. 8, 2011 from European Patent Office in corresponding EPO Application 06 769 770.6-2406 (received Apr. 18, 2011).
Glazer Steven
Rubin Keith H.
Bookstein Arthur Z.
Qian Celine
Seedlings Life Science Ventures LLC
LandOfFree
Method of risk management for patients undergoing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of risk management for patients undergoing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of risk management for patients undergoing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650316